This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?
by Kinjel Shah
When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
by Kinjel Shah
J&J announces Q4 earnings. FDA approves AZN and Daiichi's Dato-DXd for breast cancer.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
by Kinjel Shah
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $66.58, representing a -0.09% change from its previous close.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Sanofi Down 10% in 3 Months: How Should You Play the Stock?
by Kinjel Shah
SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline progress are good enough reasons to stay invested in the stock
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates with blockbuster potential.
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
by Zacks Equity Research
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
by Zacks Equity Research
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.
5 Large Drug Stocks to Keep An Eye On in the New Year
by Kinjel Shah
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.
Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $66.26, representing a -0.39% change from its previous close.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
by Sundeep Ganoria
The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
by Zacks Equity Research
AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
by Kinjel Shah
NVO's novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY's Zepbound for sleep apnea.
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
by Zacks Equity Research
AstraZeneca wins approval in the EU for the label expansion of Tagrisso to treat adult patients with locally advanced, unresectable NSCLC.
Why Astrazeneca (AZN) Outpaced the Stock Market Today
by Zacks Equity Research
Astrazeneca (AZN) closed at $65.35 in the latest trading session, marking a +1.41% move from the prior day.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
by Zacks Equity Research
The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval.
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
by Zacks Equity Research
The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.